益生菌预防坏死性小肠结肠炎:荟萃分析与试验序列分析

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Journal of Clinical Pharmacy and Therapeutics Pub Date : 2023-05-08 DOI:10.1155/2023/8626191
Yang Zhang, Qiong Xu, Feng Zhang, Chunlei Sun
{"title":"益生菌预防坏死性小肠结肠炎:荟萃分析与试验序列分析","authors":"Yang Zhang, Qiong Xu, Feng Zhang, Chunlei Sun","doi":"10.1155/2023/8626191","DOIUrl":null,"url":null,"abstract":"What is Known and Objective. The role of probiotics, especially the different genera of probiotics, in managing necrotizing enterocolitis (NEC) is controversial. Thus, we performed a meta-analysis with trial sequential analysis (TSA) to determine the efficacy and safety of probiotics for preventing NEC. Methods. Medline, Embase, CENTRAL, WorldCat, TROVE, DART-Europe, and CBM were searched from inception to May 2022. Two investigators independently screened the literature, extracted data, and assessed the quality of the included studies. Meta-analysis was performed using RevMan 5.4, and TSA was conducted using TSA 0.9 beta. Results and Discussion. Fifty-five studies involving 12897 newborns were eligible. The use of probiotics for preventing NEC reduced the incidence of NEC (RR 0.48, 95% CI 0.41 to 0.57, and \n \n P\n \n  < 0.05) and sepsis (RR 0.77, 95% CI 0.64 to 0.94, and \n \n P\n \n  < 0.05), the risk of mortality (RR 0.69, 95% CI 0.58 to 0.84, and \n \n P\n \n  < 0.05), and shortened the average days of hospitalization (MD −3.12, 95% CI −4.98 to −1.26, and \n \n P\n \n  < 0.05). However, subgroup analysis revealed that different genera of probiotics gave rise to different outcomes. In addition, TSA indicated that the cumulative z-curve crossed the traditional and trial sequential monitoring boundaries for benefit, providing firm evidence that multiple strains and Lactobacillus species of probiotics decreased the incidence of NEC. However, the current evidence was inconclusive for Bifidobacterium and Saccharomyces species. What is New and Conclusions. Probiotics are effective in preventing NEC and sepsis and could provide added benefits, including decreasing mortality and the number of days of hospitalization. However, considering the heterogeneity of probiotics regimens and the risk of selective reporting of RCTs, more high-quality clinical trials targeting different genera of probiotics with suitable doses and timing to prophylactic use of probiotics are needed to avoid overestimating the role of probiotics in preterm infants.","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2023-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Probiotics for Preventing Necrotizing Enterocolitis: A Meta-Analysis with Trial Sequential Analysis\",\"authors\":\"Yang Zhang, Qiong Xu, Feng Zhang, Chunlei Sun\",\"doi\":\"10.1155/2023/8626191\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"What is Known and Objective. The role of probiotics, especially the different genera of probiotics, in managing necrotizing enterocolitis (NEC) is controversial. Thus, we performed a meta-analysis with trial sequential analysis (TSA) to determine the efficacy and safety of probiotics for preventing NEC. Methods. Medline, Embase, CENTRAL, WorldCat, TROVE, DART-Europe, and CBM were searched from inception to May 2022. Two investigators independently screened the literature, extracted data, and assessed the quality of the included studies. Meta-analysis was performed using RevMan 5.4, and TSA was conducted using TSA 0.9 beta. Results and Discussion. Fifty-five studies involving 12897 newborns were eligible. The use of probiotics for preventing NEC reduced the incidence of NEC (RR 0.48, 95% CI 0.41 to 0.57, and \\n \\n P\\n \\n  < 0.05) and sepsis (RR 0.77, 95% CI 0.64 to 0.94, and \\n \\n P\\n \\n  < 0.05), the risk of mortality (RR 0.69, 95% CI 0.58 to 0.84, and \\n \\n P\\n \\n  < 0.05), and shortened the average days of hospitalization (MD −3.12, 95% CI −4.98 to −1.26, and \\n \\n P\\n \\n  < 0.05). However, subgroup analysis revealed that different genera of probiotics gave rise to different outcomes. In addition, TSA indicated that the cumulative z-curve crossed the traditional and trial sequential monitoring boundaries for benefit, providing firm evidence that multiple strains and Lactobacillus species of probiotics decreased the incidence of NEC. However, the current evidence was inconclusive for Bifidobacterium and Saccharomyces species. What is New and Conclusions. Probiotics are effective in preventing NEC and sepsis and could provide added benefits, including decreasing mortality and the number of days of hospitalization. However, considering the heterogeneity of probiotics regimens and the risk of selective reporting of RCTs, more high-quality clinical trials targeting different genera of probiotics with suitable doses and timing to prophylactic use of probiotics are needed to avoid overestimating the role of probiotics in preterm infants.\",\"PeriodicalId\":15381,\"journal\":{\"name\":\"Journal of Clinical Pharmacy and Therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Pharmacy and Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/8626191\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacy and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/8626191","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

什么是已知的和客观的。益生菌,特别是不同属的益生菌,在管理坏死性小肠结肠炎(NEC)中的作用是有争议的。因此,我们采用试验序列分析(TSA)进行了荟萃分析,以确定益生菌预防NEC的有效性和安全性。方法。Medline、Embase、CENTRAL、WorldCat、TROVE、DART Europe和CBM从成立到2022年5月进行了搜索。两名研究人员独立筛选了文献,提取了数据,并评估了纳入研究的质量。使用RevMan 5.4进行荟萃分析,使用TSA 0.9β进行TSA。结果和讨论。55项研究涉及12897名新生儿,符合条件。使用益生菌预防NEC降低了NEC的发生率(RR 0.48,95%CI 0.41至0.57,P < 0.05)和败血症(RR 0.77,95%CI 0.64至0.94,P < 0.05),死亡率(RR 0.69,95%CI 0.58-0.84,P < 0.05),并缩短了平均住院天数(MD−3.12,95%CI−4.98至−1.26,P < 0.05)。然而,亚组分析显示,不同属的益生菌产生不同的结果。此外,TSA表明,累积z曲线跨越了传统和试验顺序监测的界限,为益生菌的多种菌株和乳杆菌物种降低NEC的发病率提供了确凿证据。然而,目前的证据对双歧杆菌和酿酒酵母物种没有定论。新内容和结论。益生菌可有效预防NEC和败血症,并可提供额外的益处,包括降低死亡率和住院天数。然而,考虑到益生菌方案的异质性和随机对照试验选择性报告的风险,需要针对不同种类的益生菌进行更高质量的临床试验,并在适当的剂量和时间内预防性使用益生菌,以避免高估益生菌在早产儿中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Probiotics for Preventing Necrotizing Enterocolitis: A Meta-Analysis with Trial Sequential Analysis
What is Known and Objective. The role of probiotics, especially the different genera of probiotics, in managing necrotizing enterocolitis (NEC) is controversial. Thus, we performed a meta-analysis with trial sequential analysis (TSA) to determine the efficacy and safety of probiotics for preventing NEC. Methods. Medline, Embase, CENTRAL, WorldCat, TROVE, DART-Europe, and CBM were searched from inception to May 2022. Two investigators independently screened the literature, extracted data, and assessed the quality of the included studies. Meta-analysis was performed using RevMan 5.4, and TSA was conducted using TSA 0.9 beta. Results and Discussion. Fifty-five studies involving 12897 newborns were eligible. The use of probiotics for preventing NEC reduced the incidence of NEC (RR 0.48, 95% CI 0.41 to 0.57, and P  < 0.05) and sepsis (RR 0.77, 95% CI 0.64 to 0.94, and P  < 0.05), the risk of mortality (RR 0.69, 95% CI 0.58 to 0.84, and P  < 0.05), and shortened the average days of hospitalization (MD −3.12, 95% CI −4.98 to −1.26, and P  < 0.05). However, subgroup analysis revealed that different genera of probiotics gave rise to different outcomes. In addition, TSA indicated that the cumulative z-curve crossed the traditional and trial sequential monitoring boundaries for benefit, providing firm evidence that multiple strains and Lactobacillus species of probiotics decreased the incidence of NEC. However, the current evidence was inconclusive for Bifidobacterium and Saccharomyces species. What is New and Conclusions. Probiotics are effective in preventing NEC and sepsis and could provide added benefits, including decreasing mortality and the number of days of hospitalization. However, considering the heterogeneity of probiotics regimens and the risk of selective reporting of RCTs, more high-quality clinical trials targeting different genera of probiotics with suitable doses and timing to prophylactic use of probiotics are needed to avoid overestimating the role of probiotics in preterm infants.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.10
自引率
5.00%
发文量
226
审稿时长
6 months
期刊介绍: The Journal of Clinical Pharmacy and Therapeutics provides a forum for clinicians, pharmacists and pharmacologists to explore and report on issues of common interest. Reports and commentaries on current issues in medical and pharmaceutical practice are encouraged. Papers on evidence-based clinical practice and multidisciplinary collaborative work are particularly welcome. Regular sections in the journal include: editorials, commentaries, reviews (including systematic overviews and meta-analyses), original research and reports, and book reviews. Its scope embraces all aspects of clinical drug development and therapeutics, including: Rational therapeutics Evidence-based practice Safety, cost-effectiveness and clinical efficacy of drugs Drug interactions Clinical impact of drug formulations Pharmacogenetics Personalised, stratified and translational medicine Clinical pharmacokinetics.
期刊最新文献
Medication Errors: An Update From the Central Region of Ghana Synergistic Inhibitory Effect of Gliquidone Against Cisplatin-Resistant Human Lung Adenocarcinoma TH-302: A Highly Selective Hypoxia-Activated Prodrug for Treating PARP Inhibitor–Resistant Cancers Potential Role of APC Mutations in the Prognosis and Targeted Therapy of Gastric Adenocarcinoma The Evaluation for Expandable Applications of Tislelizumab in First-Line Treatment for Advanced Gastric Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1